Business Wire Feed
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver cancer Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 span all three major subtypes of metastatic breast cancer CARES Phase more...
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO) Annual more...
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026
MORRISVILLE, N.C.--(BUSINESS WIRE)--#ASCO2026--SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of more...
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion more...
Kaname Capital Renews Demand for Independent Third-Party Investigation at Fukuda Denshi; Sets May 29 Deadline Ahead of June 26 AGM
BOSTON--(BUSINESS WIRE)--Kaname Capital, L.P. ("Kaname Capital") today released an open letter to the Board of Directors and Audit & Supervisory Board of Fukuda Denshi Co., Ltd. (TSE: 6960; "Fukuda Denshi"), renewing our demand for the more...
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
ZUG, Switzerland--(BUSINESS WIRE)--Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain more...
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized CareSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VCYT #ASCO26--Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, more...
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Overall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscapeAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for more...
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
33% ORR and 67% disease control observed with imneskibart triplet in metastatic melanoma following confirmed progression on potent doublet checkpoint inhibitor therapy Durable responses, Treg reduction and increased CD8/Treg ratio support imneskibart’s differentiated IL-2 mechanism more...
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released more...
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast cancerIRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., a leader in precision oncology for more...
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company’s differentiated pipeline including pumitamig, more...
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of more...
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches – – EHA Updates Include Durability of KITE-753, Kite’s Enhanced DuoCore™ more...
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
Flatiron's real-world evidence research and live Flatiron Telescope demonstrations at booth #21149 showcase how scale and rigor advance oncology decision-makingNEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) more...
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
-- ETX-19477 demonstrated robust efficacy, with a 57% objective response rate in BRCA-mutated platinum-resistant ovarian cancer and earlier-line HR+/HER2- breast cancer (n=7) -- -- Favorable safety profile, including low rates of hematologic toxicity, supports further more...
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral more...
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Noetik’s TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival In a retrospective analysis of refractory MSS metastatic colorectal cancer without active more...
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
New findings in kidney, liver and prostate cancers reflect the shift toward more personalized, biology-driven treatment.LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in more...
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic more...
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer
Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting provide updates on EVEREST-2 and describe approaches to boost potency and preserve selectivity of TmodTM-based precision cell therapiesCHICAGO--(BUSINESS WIRE)--#ASCO26--A2 Biotherapeutics, Inc. (A2 more...
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in more...
BioVigil Appoints Brad Ryba as Chief Technology Officer to Accelerate Innovation and Market Expansion
ANN ARBOR, Mich.--(BUSINESS WIRE)--BioVigil, the market leader in electronic hand hygiene and infection prevention technology, has hired Brad Ryba as the company’s Chief Technology Officer (CTO). Ryba will lead the company’s technology and data strategy, more...
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment more...
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35%PITTSBURGH & CLEVELAND--(BUSINESS WIRE)--#AI--A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research more...